IFNG and cervical carcinoma: To assess the generality of aCD4 or IFN-γ/TNF-α combination as a radiosensitizer, we tested our approach on the cervical carcinoma cell line Caski, prostate carcinoma cell line DU145 and glioma cell line U373.